East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Cephalexin For Oral Suspension USP, 125 mg/5 mL and 250 mg/5 mL. Aurobindo Pharma’s Cephalexin For Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), Keflex for Oral Suspension, manufactured by Pragma Pharmaceuticals, LLC.

Cephalexin For Oral Suspension are indicated for the treatment of:

• Respiratory Tract Infections
• Otitis Media
• Skin and Skin Structure Infections
• Bone Infections
• Genitourinary Tract Infections